Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations

Ann Oncol. 2018 May 1;29(5):1331-1333. doi: 10.1093/annonc/mdy087.

Authors

Y Taniguchi¹, A Tamiya², S Ishii², S Atagi³

Affiliations

¹ Department of Internal Medicine, Sakai City, Osaka, Japan. Electronic address: yoshi-taniguchi@kch.hosp.go.jp.
² Department of Internal Medicine, Sakai City, Osaka, Japan.
³ Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai City, Osaka, Japan.

PMID: 29522162
DOI: 10.1093/annonc/mdy087

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage*
Antineoplastic Agents, Immunological / administration & dosage*
B7-H1 Antigen / metabolism
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
ErbB Receptors / genetics
Female
Humans
Lung / diagnostic imaging
Lung / pathology
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Middle Aged
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden / drug effects

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
pembrolizumab
EGFR protein, human
ErbB Receptors